Rebion

Rebion's blinq.® vision scanner is the first and only device FDA-cleared for detection of amblyopia and strabismus.

This new technology was designed to identify functional impairments in the brain to directly detect amblyopia, often referred to as lazy eye. 1 in 20 children suffer from this disease and if not caught during early childhood, the effects of this disease remain permanent into adulthood.

The 2-second blinq test conducts a retinal polarization scan of the fovea to determine if a child can achieve sound binocular function. With unprecedented accuracy, pediatricians, charitable and public health organizations can confidently "pass" healthy patients while prioritizing the importance of a "refer" for patients in need of follow-up care.